The MATWIN program is an activity installed by the French Government as a collaboration with Pharma companies, investors and patient advocacy groups to accelerate development of future oncology treatments.
Projects selected in the MATWIN process are characterized by high quality science and a ground-breaking potential to make a difference for cancer patients. In the selection process candidate projects are on the one hand scrutinized and on the other hand receiving support and advice from the program partners (e.g., Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, Gilead, GlaxoSmithKline, Janssen, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) that are concerned with sourcing and supporting projects with a high industrial development potential. The final event will take place October 13-14, 2020.
Scandion Oncology CSO, Nils Brünner comments
“We are very pleased about the MATWIN opportunity. We have been through several selection rounds as well as several coaching events. Scandion Oncology has now reached the final step where we will present Scandion Oncology for world leading oncology pharma companies. Moreover, MATWIN has assembled a group of biotech investors to whom we will present our program as a potential investment case.
The MATWIN program has been a great opportunity for Scandion Oncology. It is a highly professional program which helps biotech companies to progress their projects, to collaborate with pharma companies in the oncology space and to find international investors.”
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 3, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.